New study aims to make Weight-Loss drug easier to tolerate
NCT ID NCT07574723
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests whether a flexible, symptom-guided dosing plan for tirzepatide can reduce nausea and vomiting compared to the standard dosing plan in adults with obesity who do not have diabetes. Participants will be randomly assigned to one of two dosing strategies and followed for 76 weeks. The goal is to improve tolerability and help people stay on treatment longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dasman Diabetes Institute
RECRUITINGKuwait City, 15462, Kuwait
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?